Back to search results

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Somatostatin Receptor Positive · NETs · Lymphoma · Solid Tumor · CNS Tumors · Rhabdomyosarcoma · Peripheral Primitive Neuroectodermal Tumor · GIST

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Theodore W. Laetsch, MD) · laetscht@chop.edu

  • University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (David McCall, MD) · dmccall1@mdanderson.org

  • Gustave Roussy Cancer Campus, Villejuif, France

    Contact: Study coordinator (Charlotte Rigaud, Dr.) · charlotte.rigaud@gustaveroussy.fr

  • Hospital Universitario Vall d'Hebron - Oncología Médica, Barcelona, Spain

    Contact: Study coordinator (Lucas Moreno, Dr.) · lucas.moreno@vallhebron.cat

  • Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Contact: Study coordinator (Cristina Mata Fernandez, Dr) · cristina.mata@salud.madrid.org · +34 915290037
Study leads

  • Roman Henkel, PhD

    Study Director

    Director, Global Clinical Operations

View source on ClinicalTrials.gov(opens in a new tab)